Extended Versus Short Dual Antiplatelet Therapy Duration After Percutaneous Coronary Intervention for Chronic Total Occlusion: A Systematic Review and Meta-Analysis.
Abstract
Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is associated with substantial ischemic risk, yet the optimal duration of dual antiplatelet therapy (DAPT) after successful CTO-PCI remains uncertain. We conducted a systematic review and meta-analysis comparing extended DAPT (>12 months) with short-term DAPT (≤12 months) following CTO-PCI. Four electronic biomedical databases were searched from inception to September 2026. Comparative studies evaluating adult patients undergoing successful CTO-PCI with drug-eluting stent implantation were eligible. Risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Three retrospective cohort studies including 3362 patients were identified, with 1761 receiving extended DAPT and 1601 receiving short-term DAPT. Extended DAPT was associated with a significantly lower risk of major adverse cardiovascular events compared with short-term DAPT (RR 0.68; 95% CI 0.55-0.84; P = 0.0004). There was no significant difference in all-cause death (RR 0.25; 95% CI 0.04-1.41; P = 0.116), myocardial infarction, stroke, cardiovascular death, major bleeding, or revascularization outcomes. However, extended DAPT was associated with a significantly higher risk of total bleeding (RR 2.34; 95% CI 1.31-4.20; P = 0.0043). Among patients undergoing successful CTO-PCI, extended DAPT was associated with lower major adverse cardiovascular events but increased total bleeding compared with DAPT ≤12 months.